XKRX
128940
Market cap4.54bUSD
Oct 08, Last price
480,500.00KRW
1D
-10.02%
1Q
23.52%
Jan 2017
57.28%
IPO
537.49%
Name
Hanmi Pharm Co Ltd
Chart & performance
P/E
35.74
P/S
3.94
EPS
13,444.46
Div yield, %
0.05%
Shrs. gr., 5y
0.12%
Rev. gr., 5y
7.54%
Revenues
1.55t
+3.48%
Net income
170.48b
+40.53%
CFO
170.15b
-12.06%
Dividend
Mar 30, 20262000 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
A globally active pharmaceutical company, Hanmi Pharm. Co., Ltd. was established in Seoul, South Korea, in 1973. The firm concentrates its efforts on researching and developing medical therapies for a range of health issues, including diabetes, obesity, cancer, autoimmune disorders, and various rare diseases.
Key people
Se Gwon Kim
Assistant Managing Director · since 2023
Jeong Hun Lee
Assistant Managing Director · since 2023
Ji Yeon Lee
Assistant Managing Director · since 2023
Sang Hyeon Lee
Assistant Managing Director · since 2024
Mun Hwa Park
Assistant Managing Director
Assistant Managing Director · since 2023
Ji Won Son
Assistant Managing Director
Assistant Managing Director
Byeong Hui Yoon
Assistant Managing Director
Yin Yeong Choi
Managing Director · since 2025
Jong Hun Yim
Co-President, Director · since 2024
Other Non-Executive Director · since 2025
Dong Guk Shin
Other Non-Executive Director · since 2025
Non-Executive Independent Director · since 2023
Yeong Gu Lee
Non-Executive Independent Director · since 2025
Do Heum Yoon
Non-Executive Independent Director · since 2023
Yeong Gak Yoon
Non-Executive Independent Director · since 2023
Legal address
서울특별시 송파구 위례성대로 14 (방이동)
한미타워
Seoul, 11 05545
KR
한미타워
Seoul, 11 05545
KR
Headquarters
경기도 화성시 팔탄면 무하로 214
한미약품
Hwaseong, 41 18536
KR
한미약품
Hwaseong, 41 18536
KR
Address
14, Wiryeseong-daero, Songpa-gu, Seoul
Hanmi Bldg
Seoul, 11 05545
KR
Hanmi Bldg
Seoul, 11 05545
KR
Address
214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do
Hanmi Pharm.
Hwaseong, 41 18536
KR
Hanmi Pharm.
Hwaseong, 41 18536
KR
Other language
Hanmi Pharm. Co., Ltd.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||